share_log

Redhill Biopharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Redhill Biopharma | 6-K:外国发行人报告

SEC announcement ·  01/26 12:54
Moomoo AI 已提取核心信息
RedHill Biopharma Ltd., a specialty biopharmaceutical company, has successfully closed a registered direct offering, raising $8 million through the sale of 10,000,000 American Depositary Shares (ADSs) at a price of $0.80 per ADS. Concurrently, the company also issued unregistered warrants to purchase an additional 10,000,000 ADSs with an exercise price of $1.00 per ADS, exercisable immediately and valid for five years. The offering was managed by H.C. Wainwright & Co., serving as the exclusive placement agent. RedHill intends to allocate the net proceeds from this offering towards general working capital, acquisitions, research and development, and other corporate purposes. The ADSs were offered under a shelf registration statement on Form F-3, declared effective by the SEC on August 9, 2021. The warrants, however, were issued in a private...Show More
RedHill Biopharma Ltd., a specialty biopharmaceutical company, has successfully closed a registered direct offering, raising $8 million through the sale of 10,000,000 American Depositary Shares (ADSs) at a price of $0.80 per ADS. Concurrently, the company also issued unregistered warrants to purchase an additional 10,000,000 ADSs with an exercise price of $1.00 per ADS, exercisable immediately and valid for five years. The offering was managed by H.C. Wainwright & Co., serving as the exclusive placement agent. RedHill intends to allocate the net proceeds from this offering towards general working capital, acquisitions, research and development, and other corporate purposes. The ADSs were offered under a shelf registration statement on Form F-3, declared effective by the SEC on August 9, 2021. The warrants, however, were issued in a private placement and, along with the ADSs underlying the warrants, have not been registered under the Securities Act, thus limiting their sale to certain conditions. The event took place on January 26, 2024, and is part of RedHill's ongoing efforts to fund its operations and development programs, including those for gastrointestinal and infectious diseases.
专业生物制药公司RedHill Biopharma Ltd.已成功完成注册直接发行,通过以每股ADS0.80美元的价格出售1,000万股美国存托股票(ADS)筹集了800万美元。同时,该公司还发行了未注册的认股权证,额外购买10,000,000份ADS,每份ADS的行使价为1.00美元,可立即行使,有效期为五年。此次发行由作为独家配售代理的H.C. Wainwright & Co. 管理。RedHill打算将本次发行的净收益分配给一般营运资金、收购、研发和其他公司用途。美国证券交易委员会于2021年8月9日宣布根据F-3表格的货架注册声明提供美国存托凭证。但是,认股权证是私募发行的,与认股权证相关的ADS尚未根据《证券法》注册,因此其出售仅限于某些条件。该活动于2024年1月26日举行,是RedHill为其运营和发展计划(包括胃肠道和传染病计划)提供资金的持续努力的一部分。
专业生物制药公司RedHill Biopharma Ltd.已成功完成注册直接发行,通过以每股ADS0.80美元的价格出售1,000万股美国存托股票(ADS)筹集了800万美元。同时,该公司还发行了未注册的认股权证,额外购买10,000,000份ADS,每份ADS的行使价为1.00美元,可立即行使,有效期为五年。此次发行由作为独家配售代理的H.C. Wainwright & Co. 管理。RedHill打算将本次发行的净收益分配给一般营运资金、收购、研发和其他公司用途。美国证券交易委员会于2021年8月9日宣布根据F-3表格的货架注册声明提供美国存托凭证。但是,认股权证是私募发行的,与认股权证相关的ADS尚未根据《证券法》注册,因此其出售仅限于某些条件。该活动于2024年1月26日举行,是RedHill为其运营和发展计划(包括胃肠道和传染病计划)提供资金的持续努力的一部分。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息